ClinicalTrials.gg
Not yet recruitingNCT07940426Updated Nov 16, 2026

Title: Clinical Performance and Outcomes After Sphere Lens Transition

An interventional study of Fanfilcon A sphere Contact lens in Astigmatism, sponsored by CooperVision International Limited (CVIL). Not yet recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by CooperVision International Limited (CVIL) (part of CooperCompanies) · Not applicable, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies in Astigmatism by CooperCompanies — 4 open to participants now, 4 under way, none of them phase 3. Astigmatism · CooperCompanies.

Planned enrollment
30th of 44
36 · median 42
Started
2026
with 4 others
No phase
44 of 45
4 open now
Registered
45th of 45
by date

Among the 45 studies in Astigmatism by CooperCompanies, this one is the 30th largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2026, is one of 44 with no phase, and was the 45th registered.

Astigmatism

418 studies on the registry are indexed under Astigmatism; 50 are open to participants now.

Browse Astigmatism studies →

Open to participants now

4 of the 45 studies in Astigmatism by CooperCompanies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Astigmatism by CooperCompanies, or all of them as a file.
02

Study summary

To evaluate subjective and clinical outcomes after transitioning from one sphere soft contact lens to another over a one-month period.

03

Conditions studied

  • Astigmatism

Keywords

  • myopia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with eyes appropriate for the study being conducted
  2. They are at least 18 years of age.
  3. They understand their rights as a research participant and are willing and able to sign a Statement of .
  4. Current habitual wearer of Biofinity soft sphere contact lenses with contact lens power ranging from +8.00 to -12.00 DS.
  5. Anisometropia no greater than 1.50D, based on contact lens power spherical equivalent.
  6. Can achieve visual acuity of at least 0.1 logMAR (20/25) in each eye with contact lenses.
  7. Able to wear the study contact lenses for 6 days a week, minimum 8 hours a day.
  8. Can be fitted with the study contact lenses (Avaira Vitality® sphere).
  9. They agree not to participate in any other clinical research study while enrolled in this study.

Exclusion criteria

Exclusion Criteria:

- 1. Anterior segment infection, inflammation or abnormality 2. Any active anterior segment ocular disease that would contraindicate contact lens wear 3. The use of systemic or ocular medications that would contraindicate contact lens wear 4. History of herpetic keratitis 5. History of refractive surgery or irregular cornea 6. Slit lamp findings that are more serious than grade 1 (ISO scale). 7. Inactive (i.e. ghost) vessels greater than 1 mm of penetration into the cornea 8. They have corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.

9. They have participated in a contact lens or contact lens care product clinical trial in the past 30 days

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Refit to Fanfilcon A Sphere Contact Lens

    Habitual wears of Confilcon A soft sphere contact lenses Refitted to Fanfilcon A sphere contact lense s and followed for one month.

    Device: Fanfilcon A sphere Contact lens

Interventions

  • DeviceFanfilcon A sphere Contact lens

    Participants are refit from their habitual sphere soft contact lenses to fanfilcon A sphere contact lenses and wear the lenses for approximately one month according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Subjective Comfort

    Subjective comfort on insertion (0-100 Visual analogue scale)

    Time frame: Baseline, 1 week, and 1 month.

07

Study locations

1 site
  • Consultorio Optométrico
    México, State of Mexico CP 06760, Mexico
    • Dr. Ruben Velazquez Guerrero, OD · Contactrubenvg@unam.mx · +525528991976
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 106 industry-sponsored interventional studies with no phase under Astigmatism, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's planned 3 months is below that.

Counting every sponsor, half of 183 studies reached it within 12 months; a quarter within 4 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 16, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940426
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Jose Vega, O.D., MSc., PhD, FAAO
Contact
JVega2@coopervision.com
9256402964
Komalpreet Kaur, BS
Contact
KoKaur@coopervision.com
9256604439

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion